Clinical Oncology reports that the FDA has granted accelerated approval to polatuzumab vedotin-piiq (Polivy) in combination with bendamustine and a rituximab product (BR) to treat adult patients with diffuse large B-cell lymphoma (DLBCL) that has progressed or...